




RealRate

# PHARMACEUTICAL 2026

Arrowhead Pharmaceuticals INC  
Rank 89 of 178



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Arrowhead Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arrowhead Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Arrowhead Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is 230%, being 0.54% points above the market average of 229%.

| Input Variable                              | Value in 1000 USD | Output Variable             | Value in 1000 USD |
|---------------------------------------------|-------------------|-----------------------------|-------------------|
| Assets, Current                             | 950,639           | Assets                      | 1,385,295         |
| Cost of Goods Sold                          | 0                 | Liabilities                 | 881,879           |
| Intangible Assets                           | 6,861             | Expenses                    | 752,521           |
| Liabilities, Current                        | 195,487           | Revenues                    | 829,448           |
| Liabilities, Non-Current                    | 686,392           | Stockholders Equity         | 503,416           |
| Other Assets                                | 45,280            | Net Income                  | 30,114            |
| Other Compr. Net Income                     | 1,693             | Comprehensive Net Income    | 30,960            |
| Other Expenses                              | 21,419            | BaseVar                     | 1,948,824         |
| Other Liabilities                           | 0                 | ECR before LimitedLiability | 100%              |
| Other Net Income                            | -46,813           | Economic Capital Ratio      | 230%              |
| Other Revenues                              | 829,448           |                             |                   |
| Property and Equipment                      | 382,515           |                             |                   |
| Research and Development                    | 607,159           |                             |                   |
| Selling, General and Administrative Expense | 123,943           |                             |                   |